Shammas F V, Heikkilä R
Medisinsk avdeling Sentralsjukehuset i Rogaland, Stavanger.
Tidsskr Nor Laegeforen. 1997 Nov 30;117(29):4220-2.
Secondary or therapy related myelodysplastic syndrome may develop following treatment with alkylating agents and radiotherapy. The condition may also follow high dose therapy for malignant lymphomas. We describe two patients who developed secondary myelodysplasia. The first is a 76-year old female with a low grade lymphoma who developed pancytopenia with monosomy 7. Secondary myelodysplasia was diagnosed 24 months after treatment with chlorambucil (total dose of 900 mg) and 12 months after treatment with trophosphamide (total dose of 24 g). The second patient was a 48-year old male who underwent autologous bone marrow transplantation for a relapsed low grade lymphoma. Following autografting he had persistent anemia and trombocytopenia. Secondary myelodysplastic syndrome with complex karyotype was diagnosed 54 months after high dose therapy. He died nine months later of bone marrow failure.
继发性或治疗相关的骨髓增生异常综合征可能在使用烷化剂和放疗后发生。这种情况也可能在恶性淋巴瘤的高剂量治疗后出现。我们描述了两名发生继发性骨髓发育异常的患者。第一名是一名76岁的女性，患有低度淋巴瘤，出现全血细胞减少伴7号染色体单体。在使用苯丁酸氮芥（总剂量900毫克）治疗24个月后和使用环磷酰胺（总剂量24克）治疗12个月后，诊断为继发性骨髓增生异常。第二名患者是一名48岁的男性，因复发性低度淋巴瘤接受了自体骨髓移植。自体移植后，他持续存在贫血和血小板减少。在高剂量治疗54个月后，诊断为具有复杂核型的继发性骨髓增生异常综合征。九个月后，他死于骨髓衰竭。
